Bayer is working on expanding the label for its chronic kidney disease drug Kerendia, announcing three new trials to investigate it as a treatment for heart failure.
MOONRAKER will add 9,000 new patients, expanding the clinical development program to about 15,000 participants and making it one of the largest heart failure study programs, Bayer claims. CPC Clinical Research, a non-profit academic research organization affiliated with the University of Colorado, is conducting the Bayer-funded trials with other institutions.
The German drugmaker already has a Phase III trial called FINEARTS-HF, in which the company is investigating Kerendia versus standard-of-care and placebo in 6,000 patients with heart failure and mildly reduced or preserved ejection fraction.
The new trials will test the drug in patients with reduced ejection infraction (HfrEF), mildly reduced HfmrEF or preserved HfpEF.
“We aim to gain a comprehensive understanding of the potential of finerenone for the…
Click here to view original post
